Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
Studies underline that a tumour-agnostic approach may help improve treatment options
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.